$14.14
3.87% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Oculis Stock price

$14.14
-0.26 1.81% 1M
+2.13 17.74% 6M
+2.91 25.91% YTD
+4.33 44.14% 1Y
+3.98 39.17% 3Y
+3.98 39.17% 5Y
+3.98 39.17% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.57 3.87%
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Key metrics

Market capitalization $590.28m
Enterprise Value $460.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.70
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-71.77m
Free Cash Flow (TTM) Free Cash Flow $-57.69m
Cash position $125.03m
EPS (TTM) EPS $-2.00
P/E forward negative
P/S forward 607.72
EV/Sales forward 479.32
Short interest 0.05%
Show more

Is Oculis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Oculis Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Oculis forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Oculis forecast:

Buy
100%

Financial data from Oculis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.35 0.35
-
-
-0.35 -0.35
-
-
- Selling and Administrative Expenses 22 22
2% 2%
-
- Research and Development Expense 49 49
0% 0%
-
-71 -71
-
-
- Depreciation and Amortization 0.35 0.35
-
-
EBIT (Operating Income) EBIT -72 -72
0% 0%
-
Net Profit -75 -75
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about Oculis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oculis Stock News

Neutral
GlobeNewsWire
3 days ago
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Neutral
GlobeNewsWire
3 days ago
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Neutral
GlobeNewsWire
9 days ago
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended September 30, 2024, and provided an overview of the Company's progress.
More Oculis News

Company Profile

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Riad Sherif
Employees 36
Founded 2016
Website oculis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today